Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01763918 · ClinicalTrials.gov registry record · Phase 3
Reduction of LDL-C With PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder Study-2
A Phase 3 study of Hyperlipidemia, sponsored by Amgen.
- Completed
- Registry status
- Phase 3
- Development phase
- 331
- Enrollment target
- 20
- Study locations
NCT01763918 is a Phase 3 study of Hyperlipidemia that has completed, run by Amgen. The registered enrollment target is 331 participants, below the 398-participant average among 35 other Hyperlipidemia trials with a reported enrollment target (17% lower). The trial reports 20 study locations across 8 states.
The verdict
NCT01763918, a Phase 3 study of Hyperlipidemia, has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 331 participants
- Enrollment target
- 20
- Study locations
Study Summary
The primary objective was to evaluate the effect of 12 weeks of evolocumab subcutaneously once every 2 weeks (Q2W) and once monthly (QM), compared with placebo, on percent change from baseline in low-density lipoprotein cholesterol (LDL-C) in adults with heterozygous familial hypercholesterolemia (HeFH).
Conditions Studied
Interventions
- DRUG Placebo
- BIOLOGICAL Evolocumab
Study Locations (20)
Other
- Research Site - Bron
- Research Site - Nantes
- Research Site - Paris
- Research Site - Cologne
- Research Site - New Territories
- Research Site - Amersfoort
- Research Site - Amsterdam
- Research Site - Amsterdam
- Research Site - Gouda
- Research Site - Groningen
- Research Site - Hoorn
Quebec
- Research Site - Chicoutimi
- Research Site - Montreal
- Research Site - Montreal
Arizona
- Research Site - Scottsdale
Ohio
- Research Site - Cincinnati
New South Wales
- Research Site - Camperdown
Western Australia
- Research Site - Perth
British Columbia
- Research Site - Vancouver
Ontario
- Research Site - London
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 331 participants |
| Start Date | 2013-02-07 |
| Est. Completion | 2013-12-19 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01763918
The ClinicalTrials.gov registry entry for NCT01763918 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 331 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 398-participant average among 35 other Hyperlipidemia trials with a reported enrollment target (17% lower). The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hyperlipidemia appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT01763918 reports 20 study locations spanning 8 distinct geographic areas - top geographies include Other, Quebec, Arizona.
Frequently Asked Questions
What is clinical trial NCT01763918 about?
NCT01763918 is a clinical study titled "Reduction of LDL-C With PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder Study-2". The primary objective was to evaluate the effect of 12 weeks of evolocumab subcutaneously once every 2 weeks (Q2W) and once monthly (QM), compared with placebo, on percent change from baseline in low-density lipoprotein cholesterol (LDL-C) in adults with heterozygous familial hypercholesterolemia (H...
What is the current status of trial NCT01763918?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 331 participants. The study started on 2013-02-07. Estimated completion is 2013-12-19.
What conditions does trial NCT01763918 study?
This clinical trial studies the following conditions: Hyperlipidemia.
What interventions are being tested in trial NCT01763918?
The interventions under investigation include: Placebo (DRUG), Evolocumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT01763918?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01763918 being conducted?
This trial has 20 study locations across Arizona, Ohio, New South Wales, Western Australia, British Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hyperlipidemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Clinical Study of Enlicitide in Participants With High Cholesterol (MK-0616-037)
RECRUITING · Phase 3
-
Compassionate Use of Metreleptin in Previously Treated People With Generalized Lipodystrophy
ACTIVE NOT RECRUITING · Phase 3
-
Low Carbohydrate Diet Compared to Calorie and Fat Restricted Diet in Patients With Obesity and Type II Diabetes
COMPLETED · Phase 3
-
Changes in Lipids and Safety of Raltegravir in HIV+ Patients With Hyperlipidemia While on Current Standard Therapy
COMPLETED · Phase 3
-
Effects of Colesevelam HCl, Rosiglitazone, Sitagliptin on Control of Blood Glucose and Lipids in Type 2 Diabetes Patients Whose Blood Glucose Isn't Completely Controlled With Metformin
COMPLETED · Phase 3
-
A Coronary IVUS Study to Compare Torcetrapib/Atorvastatin to Atorvastatin Alone in Subjects With Coronary Heart Disease
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.